SCHEMBL323295

SCHEMBL323295

O=C(O)C(O)c1ccc(Br)cc1

nearest known ligand 0.62

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.62
MAPK1 P28482 1/20 0.62
LDHA P00338 1/20 0.47
CYP1A2 P05177 1/20 0.47
FPR2 P25090 1/20 0.43
BLM P54132 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 1/20 0.43
CES2 O00748 1/20 0.42
CES1 P23141 1/20 0.42
KMT2A Q03164 2/20 0.42
CNR1 P21554 2/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
MEN1 O00255 1/20 0.42
CYP2C19 P33261 1/20 0.41
ALOX5 P09917 1/20 0.41
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29903941 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL10170603 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL503470 1.00 LMNA (0.62) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL8997394 0.94 LMNA (0.56) LMNAMAPK1LDHACYP1A2FPR2
SCHEMBL275597 0.87 LMNA (0.79) LMNAMAPK1BLMNPSR1TSHR
SCHEMBL25309981 0.79 MEN1 (0.49) LMNAMAPK1CYP1A2CES2CES1
SCHEMBL5778110 0.79 CYP1A2 (0.55) CYP1A2CES2CES1CNR1SMN1; SMN2
SCHEMBL14215891 0.79 HPGD (0.48) LMNAMAPK1LDHACYP1A2KMT2A
SCHEMBL467741 0.78 LMNA (0.65) LMNAMAPK1BLMNPSR1TSHR
SCHEMBL20930835 0.78 CYP2D6 (0.61) LDHACYP1A2FPR2CES2CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12096767-B2 Residual disinfectant composition KIMBERLY-CLARK WORLDWIDE, INC. (US) 2024-09-24 US claimed
EP-3725153-B1 RESIDUAL DISINFECTANT COMPOSITION KIMBERLY CLARK CO (US) 2024-09-04 EP claimed
CN-108884081-B Process for separating enantiomers of piperazine derivatives 阿森纽荣股份公司 2022-11-01 CN claimed
CN-111056890-B Method for preparing aryl ketone by free radical-free radical coupling reaction of ketoacid decarboxylation and fatty aldehyde decarbonylation based on iron catalysis 湘潭大学 2022-10-14 CN claimed
US-20220325035-A1 POLYESTER, POLYESTERAMIDE, AND POLYAMIDE COMPOSITIONS IYER ANANTH V (US) 2022-10-13 US claimed
CN-113831233-B Synthesis method and application of 2, 2-bis (4-bromophenyl) -2-hydroxyacetic acid 江苏禾本生化有限公司 2022-09-02 CN claimed
CN-113831233-A Synthetic method and application of 2,2,2 (4-bromophenyl) -2-glycolic acid 江苏禾本生化有限公司 2021-12-24 CN claimed
EP-3419974-B1 PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES ASCENEURON SA (CH) 2021-05-05 EP claimed
US-20210092949-A1 Residual Disinfectant Composition KIMBERLY-CLARK WORLDWIDE, INC. 2021-04-01 US claimed
US-10874100-B2 Residual disinfectant composition KIMBERLY-CLARK WORLDWIDE, INC. (US) 2020-12-29 US claimed
US-20180199567-A1 Residual Disinfectant Composition KIMBERLY-CLARK WORLDWIDE, INC. 2018-07-19 US claimed
EP-3337324-A1 RESIDUAL DISINFECTANT COMPOSITION Kimberly-Clark Worldwide, Inc. (US) 2018-06-27 EP claimed
WO-2017144635-A1 PROCESS FOR THE SEPARATION OF ENANTIOMERS OF PIPERAZINE DERIVATIVES ASCENEURON S. A. (CH) 2017-08-31 WO claimed
WO-2017019009-A1 RESIDUAL DISINFECTANT COMPOSITION KIMBERLY-CLARK WORLDWIDE, INC. (US) 2017-02-02 WO claimed
CN-1703396-A Novel propargylether derivatives for controlling phytopathogenic microorganisms SYNGENTA PARTICIPATIONS AG (CH) 2005-11-30 CN claimed
WO-2003103579-A2 HIGH-THROUGHPUT METHODS AND SYSTEMS FOR SCREENING OF COMPOUNDS TO TREAT/PREVENT KIDNEY DISORDERS TRANSFORM PHARMACEUTICALS, INC. (US) 2003-12-18 WO claimed
EP-1124417-A2 COMPOSITIONS COMPRISING PLANT CELL GROWTH REGULATING COMPOUNDS AND METHODS OF USE THEREOF INVITROGEN CORPORATION (US) 2001-08-22 EP claimed
WO-2000024249-A2 COMPOSITIONS COMPRISING PLANT CELL GROWTH REGULATING COMPOUNDS AND METHODS OF USE THEREOF INVITROGEN CORPORATION (US) 2000-05-04 WO claimed
US-5683793-A Ink jet transparencies XEROX CORPORATION (US) 1997-11-04 US claimed
US-5589277-A INK JET PRINTING, AQUEOUS INKS, FAST DRYING XEROX CORPORATION (US) 1996-12-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180199567-A1 Residual Disinfectant Composition QARS1, EIF2AK2, POLL LMNA 1914/4885MAPK1 4353/4885LDHA 2716/4885
US-20210092949-A1 Residual Disinfectant Composition QARS1, EIF2AK2, POLL LMNA 1914/4885MAPK1 4353/4885LDHA 2716/4885
US-12096767-B2 Residual disinfectant composition QARS1, EIF2AK2, POLL LMNA 1914/4885MAPK1 4353/4885LDHA 2716/4885
US-10874100-B2 Residual disinfectant composition QARS1, EIF2AK2, POLL LMNA 1914/4885MAPK1 4353/4885LDHA 2716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.